Speaker illustration

Doctor Margaret Sketch

United Therapeutics Corporation, Research Triangle Park (United States of America)

Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review

Event: ESC Congress 2022

Topic: Pulmonary Hypertension

Session: Treatment of pulmonary arterial hypertension: the old and the new


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb